Rigel Pharmaceuticals, Inc./$RIGL
1D1W1MYTD1Y5YMAX
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Ticker
- $RIGL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 173
- Headquarters
- South San Francisco, United States
- Website
- www.rigel.com
RIGL Metrics
BasicAdvanced
$795M
2.59
$16.45
1.17
-
Price and volume
Market cap
$795M
Beta
1.17
52-week high
$52.24
52-week low
$24.95
Average daily volume
337K
Financial strength
Current ratio
1.941
Quick ratio
1.584
Long term debt to equity
0.014
Total debt to equity
9.391
Interest coverage (TTM)
15.00%
Profitability
EBITDA (TTM)
89.699
Gross margin (TTM)
75.61%
Net profit margin (TTM)
116.30%
Operating margin (TTM)
31.45%
Effective tax rate (TTM)
-276.17%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
14.95%
Return on equity (TTM)
126.90%
Valuation
Price to earnings (TTM)
2.588
Price to revenue (TTM)
2.815
Price to book
1.87
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
86.184
Free cash flow yield (TTM)
1.16%
Free cash flow per share (TTM)
0.494
Growth
Revenue change (TTM)
3.31%
Earnings per share change (TTM)
202.71%
3-year revenue growth (CAGR)
31.71%
10-year revenue growth (CAGR)
22.92%
3-year earnings per share growth (CAGR)
96.14%
10-year earnings per share growth (CAGR)
11.41%
RIGL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.